Benitec Biopharma Inc. (BNTC) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Hayward, CA, United States. El CEO actual es Jerel A. Banks.
BNTC tiene fecha de IPO 2014-06-24, 16 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $347.77M.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
